Nykode Therapeutics (Vaccibody) småprat (NYKD)

[h3nk1]

For en oppriktig ubrukelig artikkel (og journalist).

[frank89]

vi kan stole på sjernene!

[Kvadro]

Det er nok mest clickbait som gjelder her. Er nok litt det samme som Tore aksel voldberg sin exit. Sånt generer mye trafikk.

Vil tro de som går short ser mest til makro, og ikke til forskningsresultater.

Selskap med relativt høy prising og lav inntjening tiltrekker seg shortere som “flua på hæstskiten” i dette klimaet.

[safin]

Arne Fredly, Edvin Austbø og Johan Johansson kjøpte Voldbergs Nykode-aksjer

[Boms]

Interessant:
https://newsweb.oslobors.no/message/600981
Nykode viser prekliniske resultater med mRNA som alternativ levering.

PS @pdx varsling fra Newsweb sliter litt i dag, nyheter i flere aksjer mangler

[pdx]

TekBot er ute av drift inntil videre

TekBot er ute av drift inntil videre pga tekniske problemer, så det vil ikke bli publisert nye børsmeldinger automatisk. Er på saken

[TekBot]

Nykode Therapeutics to Present at the mRNA Cancer Vaccines Summit 2023 in Boston

• Nykode’s APC targeted vaccine technology can be delivered as mRNA and generate strong T cell responses
• Nykode’s APC targeted vaccine technology consistently results in faster, broader and stronger immune response compared to non-targeted vaccines, whether delivered as DNA or mRNA

…

Vis børsmeldingen

Oslo, Norway, October 9, 2023 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced it is presenting at the annual mRNA Cancer Vaccines Summit in Boston, Massachusetts on October 12th.

Mikkel W. Pedersen, Chief Scientific Officer at Nykode will present preclinical data highlighting the differentiating factors of Nykode’s proprietary vaccine technology. When delivered either via DNA or mRNA, Nykode’s Antigen presenting cells (APC)-targeted cancer vaccines lead to a faster and broader T cell response compared to standard mRNA vaccines with identical antigens in a head-to-head comparison. There is almost a doubling of the number of antigens that are immunogenic when targeted to APCs, and the responses are primarily driven by CD8 T cells.

“These data demonstrate the strength of Nykode’s APC targeted technology to drive relevant T cell responses for cancer immunotherapy whether we use the DNA or mRNA format. Simultaneous induction of CD8 T cell responses to multiple different cancer-specific antigens holds the key to successful anti-cancer immune interventions. It is exciting to see that our unique mechanism of action targeting tumor antigens to APC leads to this unique and differentiated response,” says Mikkel W. Pedersen.

“We are very excited with these data showing that whether delivered as DNA or mRNA, Nykode’s technology results in superior immune responses. We now see the potential of Nykode’s vaccine technology to also improve the current mRNA cancer vaccines” says Michael Engsig, CEO of Nykode. “Combined with the long and durable responses observed to date in our clinical trials applying Nykode’s vaccines as DNA, we are very optimistic about the future broad application of the Vaccibody platform in the development of cancer vaccines.”

Details for the Nykode Therapeutics’ presentation are as follows:
Title: Opportunities to improve mRNA Cancer Vaccines
Time & Date: 10.00am ET, October 12, 2023

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology specifically targets antigens to APC, which have been shown to induce broad, strong and long-lasting antigen specific immune responses which correlates with clinical responses in cancer.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company’s partnerships include Genentech within oncology and a multi-target collaboration with Regeneron within oncology and infectious diseases.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics may be found at http://www.nykode.com.

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

Kilde

[TekBot]

Nykode Therapeutics to Present at the mRNA Cancer Vaccines Summit 2023 in Boston

• Nykode’s APC targeted vaccine technology can be delivered as mRNA and generate strong T cell responses
• Nykode’s APC targeted vaccine technology consistently results in faster, broader and stronger immune response compared to non-targeted vaccines, whether delivered as DNA or mRNA

…

Vis børsmeldingen

Oslo, Norway, October 9, 2023 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced it is presenting at the annual mRNA Cancer Vaccines Summit in Boston, Massachusetts on October 12th.

Mikkel W. Pedersen, Chief Scientific Officer at Nykode will present preclinical data highlighting the differentiating factors of Nykode’s proprietary vaccine technology. When delivered either via DNA or mRNA, Nykode’s Antigen presenting cells (APC)-targeted cancer vaccines lead to a faster and broader T cell response compared to standard mRNA vaccines with identical antigens in a head-to-head comparison. There is almost a doubling of the number of antigens that are immunogenic when targeted to APCs, and the responses are primarily driven by CD8 T cells.

“These data demonstrate the strength of Nykode’s APC targeted technology to drive relevant T cell responses for cancer immunotherapy whether we use the DNA or mRNA format. Simultaneous induction of CD8 T cell responses to multiple different cancer-specific antigens holds the key to successful anti-cancer immune interventions. It is exciting to see that our unique mechanism of action targeting tumor antigens to APC leads to this unique and differentiated response,” says Mikkel W. Pedersen.

“We are very excited with these data showing that whether delivered as DNA or mRNA, Nykode’s technology results in superior immune responses. We now see the potential of Nykode’s vaccine technology to also improve the current mRNA cancer vaccines” says Michael Engsig, CEO of Nykode. “Combined with the long and durable responses observed to date in our clinical trials applying Nykode’s vaccines as DNA, we are very optimistic about the future broad application of the Vaccibody platform in the development of cancer vaccines.”

Details for the Nykode Therapeutics’ presentation are as follows:
Title: Opportunities to improve mRNA Cancer Vaccines
Time & Date: 10.00am ET, October 12, 2023

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology specifically targets antigens to APC, which have been shown to induce broad, strong and long-lasting antigen specific immune responses which correlates with clinical responses in cancer.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company’s partnerships include Genentech within oncology and a multi-target collaboration with Regeneron within oncology and infectious diseases.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics may be found at http://www.nykode.com.

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

Kilde

[safin]

Ska det presenteras något nytt eller samma vanliga bla bla bla ?

[Lucrum]

Det vrker ikke som du bryr deg, men siden du spør så skal det faktisk det:

"Vitenskapelig direktør Mikkel W. Pedersen i selskapet vil presentere preklinisk data som fremhever de differensierende faktorene ved Nykodes proprietære vaksineteknologi. Når den leveres enten via DNA eller mRNA, fører Nykodes antigenpresenterende celler (APC)-målrettede kreftvaksiner til en raskere og bredere T-celle-respons sammenlignet med standard mRNA-vaksiner med identiske antigener, opplyses det.

-Vi er veldig begeistret for disse dataene som viser at Nykodes teknologi enten levert som DNA eller mRNA, resulterer i overlegne immunresponser. Vi ser nå potensialet i Nykodes vaksineteknologi for også å forbedre de nåværende mRNA kreftvaksinene, sier Michael Engsig, administrerende direktør i Nykode."

[safin]

Bryr mig väldigt men är de ikke något dom har sagt redan?

[TekBot]

Nykode Therapeutics – presentation from the mRNA Cancer Vaccines Summit 2023 in Boston

Oslo, Norway, October 12, 2023 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today presents at the annual mRNA Cancer Vaccines Summit in Boston, Massachusetts.

The presentation is held by Mikkel W. Pedersen, Chief Scientific Officer at Nykode. The presentation slides are enclosed and available in the Scientific Papers and Presentations section of the Company’s website at: Scientific papers and presentations - Nykode.
…

Vis børsmeldingen

Details for the Nykode Therapeutics’ presentation are as follows:
Title: Opportunities to improve mRNA Cancer Vaccines
Time & Date: 10.00 a.m. ET, October 12, 2023

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology specifically targets antigens to APC, which have been shown to induce broad, strong and long-lasting antigen specific immune responses which correlates with clinical responses in cancer.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company’s partnerships include Genentech within oncology and a multi-target collaboration with Regeneron within oncology and infectious diseases.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics may be found at http://www.nykode.com.

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

Kilde

[Lucrum]

Conclusions Part 1
• DNA vaccination with Vaccibodies containing
NeoAntigens result in broader T cell responses
compared to mRNA-LNP delivery of the same
NeoAntigens
• DNA vaccination with Vaccibodies containing
NeoAntigens generates superior T cell responses
following a single vaccination driven primarily by CD8
responses compared to mRNA delivery of the same
epitopes
• Similar magnitude of total T cell responses by DNA and
mRNA vaccination after boost

Conclusions Part 2
• Vaccibodies encoding T cell epitopes or structured
antigens can be delivered by mRNA and generate strong
T cell and antibody responses in animals
• mRNA vaccination with Vaccibodies containing
NeoAntigens results in broader and stronger T cell
responses compared to mRNA delivery of the same
epitopes
• mRNA vaccination with Vaccibodies is heavily CD8
focused and driven by the unique targeting to antigen
presenting cells

Antigen presenting cell targeted vaccines (nykode.com)

[safin]

Inget påverkar kursen desverre

[Lucrum]

Presentasjonen begynte 16:00 og oppdatert slidedeck ble lagt ut samtidig. Det var vel ingen som forventet eksplosive nyheter her, men det kan være at presentasjonen er interessant for endel selskaper og investorer som bruker litt mer enn 20 min på å prosessere det som ble lagt det frem🤷‍♂️

[safin]

Skjer här idag då ?

[Boms]

Sikkert tvangssalg på vegne av en belånt investor/spekulant🤷‍♂️

[safin]

Folk går konk

[Boms]

Med emojien ment jeg at jeg IKKE vet sikkert, om noen går konkurs eller havner i en skvis er trist og ikke noe jeg er likegyldig til. Har sett det skje på nært hold flere ganger og det er ikke noe hyggelig syn.

[TekBot]

Nykode Therapeutics - Update on process with the Norwegian Tax Authorities

Oslo, Norway, October 23, 2023 – Nykode Therapeutics ASA (the “Company”) refers to its interim report for the fourth quarter of 2022 and annual report for 2022, in which the Company publicly stated that the Norwegian Tax Authorities had questioned the use of taxable gain/loss account for up-front payments under a license agreement entered into in 2020, and if the payments should be recognized as taxable income in full in 2020.

As described in the reports, the effect of any change would be a reclassification of deferred tax to tax payable in the financial statements. Today the Norwegian Tax Authorities have in a formal decision reiterated their position that the payments in question should be treated as taxable income in full in 2020. This will generate a tax payable currently estimated to approximately USD 30 million.
…

Vis børsmeldingen

The Company continues to believe that the use of taxable gain/loss account is the appropriate treatment, a view which has also been confirmed with third party tax experts. As previously communicated Nykode will appeal this decision and the Company is now expected to settle the tax payable while it awaits the outcome of such appeal (as is mandatory under Norwegian law).

“We do not agree with the Norwegian Tax Authorities in this case and have received reconfirmation from leading external tax experts supporting that our use of taxable gain/loss account is the appropriate treatment. We have been prepared for today’s outcome as a potential scenario and it will as such not change any of Nykode’s operational plans to execute on the company’s strategy over the next years.” said Michael Engsig, CEO of Nykode Therapeutics.

Nykode Therapeutics had a cash position of USD 174 million at the end of the second quarter 2023.

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology specifically targets antigens to APC, which have been shown to induce broad, strong and long-lasting antigen specific immune responses which correlates with clinical responses in cancer.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer; and VB10.NEO, an individualized cancer neoantigen vaccine, which is exclusively out-licensed to Genentech, a member of the Roche Group.

The Company’s partnerships include Genentech within oncology and a multi-target collaboration with Regeneron within oncology and infectious diseases.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics may be found at http://www.nykode.com.

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

Kilde